News
 
Pharmaceuticals Newsletter - May 21 to May 25, 2012
India Infoline News Service/19:38,May 25, 2012
Piramal Healthcare Limited announced today that Phase I clinical trial data for its investigational new drug candidate P1446A-05 will be presented at the Annual Meeting of the American Society for Clinical Oncology (ASCO) being convened in Chicago from June 1-5, 2012.
list India Infoline Weekly Newsletter - May 25, 2012
list Pfizer recalls Advil bottles from distributor centers
list Teva outlines financial estimates for 2012
list Ranbaxy hires advisers for resolving consent decree with USFDA

Calendar

May-2012
M T W T F S S
21 22 23 24 25 26 27
Economic Events
list Corporate Service Price (YoY)
list Hometrack Housing Survey (MoM)
Results
list No result today
IPO
listNo IPO today
 

Piramal Healthcare to acquire further 5.5% stake in Vodafone

India Infoline News Service / 10:30 , Feb 06, 2012

The transaction follows the settlement between Vodafone and Essar over the sale of Essar’s approximately 33% stake in VIL.

Piramal Healthcare and Vodafone Group  has announced that Piramal has agreed to purchase approximately 5.5% of the issued equity share capital of Vodafone India Limited (“VIL”) from ETHL Communications Holdings Limited (“Essar”) for a cash consideration of approximately Rs3,007 crores (approximately £385 mn) taking the total shareholding of Piramal in VIL to approximately 11%.

The transaction follows the settlement between Vodafone and Essar over the sale of Essar’s approximately 33% stake in VIL, announced in July 2011, and the purchase by Piramal of approximately 5.5% of the issued share capital of VIL from Essar in August 2011.

The transaction contemplates various exit mechanisms for Piramal, including both participation in a potential initial public offering of VIL and a sale of its stake to Vodafone.

 



Rate This Article Rate 1 Rate 2 Rate 3 Rate 4 Rate 5